In our study, we found PLS3 is closely related with the TME, especially with the activation and infiltration of CD8+ T cells, suggesting that targeting PLS3 is likely to boost the anti-tumor activity of CD8+ T cells, thus improving the anti-tumor effectiveness in HNSCC. This evidence concerns the gene CD8A and neoplasm.